Revenue
2014
2015
2016
2017
2018
2019
2023
2024
2025
Synergy CHC Corp. (SNYR)
Price$0.1025Cached quote
Net income
2011
2012
2014
2015
2016
2017
2018
2019
2023
2024
2025
Free cash flow
2015
2016
2017
2018
Total cash / debt
CashTotal debt
2011
2012
2014
2015
2016
2017
2018
2019
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.4M | $34.8M | $42.8M | $29.4M | $33.8M | $35.6M | $34.8M | $13.5M | $9,158 | — | — |
| Gross profit | $20.3M | $23.6M | $32.1M | $20.2M | $22.8M | $25.8M | $24.6M | $8.1M | $3,542 | — | — |
| Gross margin | 66.83% | 67.87% | 74.99% | 68.87% | 67.37% | 72.42% | 70.71% | 60.55% | 38.68% | — | — |
| Operating expenses | $28.8M | $17.8M | $21.3M | $28.2M | $27.7M | $24.0M | $21.7M | $7.7M | $961,636 | $21,783 | $15,000 |
| Operating income | −$8.5M | $5.8M | $10.8M | −$8.0M | −$4.9M | $1.8M | $2.9M | $486,023 | −$958,094 | — | — |
| Operating margin | −27.84% | 16.65% | 25.26% | −27.10% | −14.54% | 5.12% | 8.42% | 3.61% | −10,461.83% | — | — |
| EBITDA | −$8.3M | $5.9M | $10.8M | −$6.7M | −$3.1M | $3.3M | $4.1M | $1.1M | −$958,094 | — | — |
| EBITDA margin | −27.40% | 17.04% | 25.34% | −22.97% | −9.15% | 9.31% | 11.78% | 8.13% | −10,461.83% | — | — |
| Net income | −$12.3M | $2.1M | $6.3M | −$9.2M | −$6.2M | $499,568 | −$796,161 | −$7.5M | −$960,092 | −$23,201 | −$16,200 |
| Net profit margin | −40.62% | 6.10% | 14.82% | −31.36% | −18.21% | 1.40% | −2.29% | −56.01% | −10,483.64% | — | — |
| Basic EPSper basic share | -$1.27 | $0.28 | $0.86 | -$0.10 | -$0.07 | $0.01 | -$0.01 | -$0.11 | -$0.01 | $0.00 | $0.00 |
| Diluted EPSper diluted share | -$1.27 | $0.28 | $0.86 | -$0.10 | -$0.07 | $0.01 | -$0.01 | -$0.11 | -$0.01 | $0.00 | $0.00 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Ross Jack | 4.8M |
Knight Therapeutics Inc / KNIGHT THERAPEUTICS INTERNATIONAL SA | 1.48M |
Kaushal Nitin | 306.43K |
JANE STREET GROUP, LLC | 181.65K |
ACT Advisors, LLC. | 151.84K |
SoRelle James Paul | 108.96K |
XTX Topco Ltd | 61.27K |
VANGUARD CAPITAL MANAGEMENT LLC | 38.91K |
HRT FINANCIAL LP | 34.04K |
GEODE CAPITAL MANAGEMENT, LLC | 32.78K |
Thompson Teresa Brigid | 25.82K |
Virtu Financial LLC | 18.54K |
VANGUARD FIDUCIARY TRUST CO | 16.01K |
StoneX Group Inc. | 15.11K |
EWA, LLC | 13.73K |
CITADEL ADVISORS LLC | 10.9K |
Williams & Novak, LLC | 10.02K |
Tower Research Capital LLC (TRC) | 3.71K |
BARCLAYS PLC | 884 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jul 30, 2025Form 4 | Ross JackCEO and Chairman | BuyCommon Stock, par value $0.00001 per share | 100 | $3.69 | $369.00 | 410.5K |
| Jul 29, 2025Form 4 | Ross JackCEO and Chairman | BuyCommon Stock, par value $0.00001 per share | 250 | $3.66 | $915.00 | 410.4K |
| Jul 25, 2025Form 4 | Ross JackCEO and Chairman | BuyCommon Stock, par value $0.00001 per share | 350 | $3.90 | $1.4K | 410.2K |
| Jul 24, 2025Form 4 | Ross JackCEO and Chairman | BuyCommon Stock, par value $0.00001 per share | 300 | $3.83 | $1.1K | 409.8K |
| Jul 22, 2025Form 4 | Ross JackCEO and Chairman | BuyCommon Stock, par value $0.00001 per share | 300 | $3.54 | $1.1K | 409.5K |